Guidance for industry, q & a : content and format of INDs for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products.

Other author Center for Drug Evaluation and Research (U.S.)
Other author Center for Biologics Evaluation and Research (U.S.)
Format Electronic
Publication InfoRockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, [2000]
Description1 online resource ([4] p.)
Supplemental Contenthttps://purl.fdlp.gov/GPO/LPS119805
Subjects

Variant title Guidance for industry, questions and answers
Portion of title Content and format of INDs for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products.
General note"Pharmacology/toxicology."
General note"October 2000."
General noteGPO Cataloging Record Distribution Program (CRDP).
GPO item number0499-T (online)
Govt. docs number HE 20.4702:IN 8/7 HE 20.4702:IN 8/2

Availability

Library Location Call Number Status Item Actions
Electronic Resources Access Content Online ✔ Available